@TimShannonMD

General Partner @canaanpartners

 Westport, CT
linkedin.com/in/tim-shannon-85905328
Joined September 2014
  • Tweets44
  • Following51
  • Followers236
Intercept's NASH Trial Design Irks Investors news.investors.com/technolog… #IBDNews via @IBDinvestors - $ICPT $GILD $PCYC $GEVA - need a big swing
2
Canaan Partners: Don’t Overlook Pharma Customers for Digital-Health Products on.wsj.com/1IptCgF via @WSJ -- nice stuff Julie

Canaan Partners: Don’t Overlook Pharma Customers for Digital-Health Products

Canaan Principal Julie Papanek says pharmaceutical companies are changing how they do business.

wsj.com
2
4
Spyryx Biosciences Secures $18 Million in Series A Financing - FierceBiotech: fiercebiotech.com/press-rele… -- Awesome company - important work
1
1
1
The Most Influential Women in Bay Area Business 2015 bizjournals.com/sanfrancisco… via @SFBusinessTimes - We always knew it Wende - congrats!!
1
3
4
Digital health companies see data evolution (San Diego Daily Transcript) sddt.com/Technology/article.… - Great stuff Julie!!
3
finance.yahoo.com/news/fda-a… - the start of pharma back into CV disease
2
2
onforb.es/1FLyH3A - great advice from @DeepakKamra

How To Impress A Venture Capitalist: 12 Prominent VCs Share What Gets Their Attention

Entrepreneurs seeking funding are often unsure of what they must do to get a venture capitalist's attention. So we asked 12 of them exactly what they hope to see when an entrepreneur walks through...

forbes.com
1
IMS: US prescription drug spending jumped 13 pct. in 2014 finance.yahoo.com/news/ims-u… via @YahooFinance - simply fascinating in many ways
Merck wagers $434M on Arvinas and its protein-disposal system - FierceBiotech: fiercebiotech.com/story/merc… - great companies - I'm biased!
1
2
A new cancer drug, made in China on.wsj.com/1BSKZ2B via @WSJ - amazing evolution - pricing will affect world markets with time

A New Cancer Drug, Made in China

Chinese biotechs are trying to move beyond generic medicines and develop new drugs, under the leadership of researchers that have left Big Pharma to return to their native country.

wsj.com
School is the Experiment: Self-Directed Learning as a Return to the Way Humans have Evolved to Learn northstarteens.org/school-is… - great stuff
forbes.com/sites/matthewherp… - nice story on GBM news and 60 minutes?- does data go to peer reviewed journals anymore? or just social media?
It's Time for Brands to Take Wearables to the Next Level: In an eye-opening talk... bit.ly/1BEDlwU #MPOMMA #sxsw - The future now!!

Show Daily: It's Time for Brands to Take Wearables to the Next Level

In an eye-opening talk during the opening day of SXSW 2015, leading wearable technology and fashion expert Jennifer Darmour took us beyond the hype of wearables and into the next stage of the game....

mediapost.com
Biotech’s rally fuels bubble fears on.wsj.com/1FCBICP via @WSJ - is different than 2000 but will pull back with coverage like this

Biotech’s Rally Fuels Bubble Fears

Nasdaq bubble worries are back. But this time around, some investors and analysts are looking askance at biotechnology stocks instead of tech companies.

wsj.com
1
Thomson Reuters Names Most Promising Drugs of 2015 -- prn.to/1Hrd34H - ?? when was last time 3 CV drugs in top 10??

Thomson Reuters Names Most Promising Drugs of 2015

/PRNewswire/ -- The Intellectual Property and Science business of Thomson Reuters, the world's leader in intelligent information for businesses and...

prnewswire.com
1
Biotech IPO Performance: Discerning Market Or Rising Tide? onforb.es/1Ha9TlH via @forbes - as always nice work by Bruce!
Tech Is From Mars, Biotech Is From Venus: A Handy Guide To Busting The Jargon onforb.es/18LeBHT via @forbes - Go Julie P!!
2
Scientists Seek Ban on Method of Editing the Human Genome nyti.ms/19Dizna - Impact on multiple companies founded on Crispr??

Scientists Seek Ban on Method of Editing the Human Genome (Published 2015)

A group of biologists, including the scientist who developed the technique, has called for a worldwide moratorium on using the method to change human DNA.

nytimes.com
1
Biogen Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s - yhoo.it/1BEB8Np - wow - a golden era for drugs?
1
Juno stock drops as company projects up to $150M in cash burn in first post-IPO report bit.ly/1FHJVEp -- Investors are surprised??
3
3
Load more